Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 6/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hypoxanthine SCHEMBL822613 | 0.72 | TSHR (0.47) | SMN1; SMN2TSHRRAB9ALMNAADORA2A | |
| Hypoxanthine SCHEMBL30266940 | 0.70 | TSHR (0.45) | SMN1; SMN2TSHRRAB9ALMNAADORA2A | |
| SCHEMBL14793560 | 0.68 | ALDH1A1 (0.59) | SMN1; SMN2TSHRRAB9ALMNAADORA2A | |
| Hypoxanthine SCHEMBL29533161 | 0.65 | TSHR (0.41) | SMN1; SMN2TSHRRAB9ALMNAADORA2A | |
| SCHEMBL14094281 | 0.65 | SMN1; SMN2 (0.46) | SMN1; SMN2TSHRRAB9ALMNAADORA2A | |
| SCHEMBL6379644 | 0.64 | ALDH1A1 (0.53) | SMN1; SMN2TSHRRAB9ALMNAADORA2A | |
| SCHEMBL3592847 | 0.64 | JAK2 (0.33) | PARP1JAK2PIM1 | |
| SCHEMBL21332344 | 0.64 | ALDH1A1 (0.59) | XDHALDH1A1ACHEGDA | |
| SCHEMBL3941170 | 0.63 | ACHE (0.40) | SMN1; SMN2TSHRRAB9ALMNAADORA2A | |
| SCHEMBL1992700 | 0.63 | PARP1 (0.41) | SMN1; SMN2TSHRRAB9ALMNAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143643-A1 | LOW DK COPPER CLAD LAMINATE COMPOSITIONS | DESIGNER MOLECULES INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230095931-A1 | UV-CURABLE RESIN COMPOSITIONS SUITABLE FOR REDISTRIBUTION LAYERS | DESIGNER MOLECULES INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20220213267-A1 | EXTREME HIGH TEMPERATURE STABLE ADHESIVES AND COATINGS | DESIGNER MOLECULES, INC | 2022-07-07 | — | — | US | disclosed |
| US-20220204696-A1 | PHENOLIC FUNCTIONALIZED POLYIMIDES AND COMPOSITIONS THEREOF | DESIGNER MOLECULES, INC | 2022-06-30 | — | — | US | disclosed |
| US-20220204766-A1 | HIGH MOLECULAR WEIGHT FLEXIBLE CURABLE POLYIMIDES | DESIGNER MOLECULES, INC | 2022-06-30 | — | — | US | disclosed |
| US-20210301133-A1 | CURABLE POLYIMIDES | DESIGNER MOLECULES INC (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2021113415-A1 | LOW DK COPPER CLAD LAMINATE COMPOSITIONS | DESIGNER MOLECULES, INC (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2020215025-A1 | EXTREME HIGH TEMPERATURE STABLE ADHESIVES AND COATINGS | DESIGNER MOLECULES, INC (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2020-02-27 | — | — | US | disclosed |
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-09-13 | — | — | US | disclosed |
| US-20090023765-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090018207-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-7456317-B2 | Deuterated venlafaxine derivatives; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters; for intravenous administration; tablet/capsule form | AUSPEX PHARMACEUTICALS (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070112031-A1 | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-04-12 | — | — | US | disclosed |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | HONG BORCHERNG | 2006-08-03 | — | — | US | disclosed |
| WO-2005049582-A1 | METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | SMN1; SMN2 385/4885TSHR 847/4885RAB9A 1145/4885 |
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | SMN1; SMN2 385/4885TSHR 847/4885RAB9A 1145/4885 |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | SMN1; SMN2 307/4885TSHR 677/4885RAB9A 1475/4885 |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | IDO1, TPH1, IDO2 | SMN1; SMN2 2874/4885TSHR 1484/4885RAB9A 992/4885 |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | ATP4A, ATP6V1G1, ATP6V1E1 | SMN1; SMN2 4773/4885TSHR 3119/4885RAB9A 784/4885 |
| US-20090018207-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | SMN1; SMN2 385/4885TSHR 847/4885RAB9A 1145/4885 |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | SLC6A4, HTR4, OPRK1 | SMN1; SMN2 817/4885TSHR 1585/4885RAB9A 1356/4885 |
| US-20090023765-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | SMN1; SMN2 385/4885TSHR 847/4885RAB9A 1145/4885 |
| US-20070112031-A1 | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties | SLC6A4, HTR4, HTR5A | SMN1; SMN2 613/4885TSHR 1144/4885RAB9A 1370/4885 |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | LSS, DHPS, CYP51A1 | SMN1; SMN2 4543/4885TSHR 3358/4885RAB9A 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.